Hoosier Cancer Research Network

A Thank You for Your Commitment to Advancing Cancer Research - Hoosier Cancer Research Network As we reflect on the past year, I want to thank our investigators, sites, funders, and the entire Hoosier Cancer Research Network team for your continued commitment to investigator-initiated cancer re...

CEO Brian Stemme reflects on a year of progress and collaboration at HCRN. Read more: hoosiercancer.org/a-thank-you-...

HCRN welcomes Anna Pavlick, DO, MBA (Weill Cornell), Michael C. Lowe, MD, MA (Emory Winship), and Arkadiusz Z. Dudek, MD, PhD (Mayo Clinic) as co-chairs of the Melanoma Clinical Trial Working Group.

👉 Read more: hoosiercancer.org/collaborativ...

#HCRN #Melanoma #CancerResearch

HCRN welcomes Neelima Vidula, MD (Mass General Hospital) & Alison Conlin, MD, MPH (Providence Cancer Institute) as co-chairs of the Breast Cancer Clinical Trial Working Group, joining Carey Anders, MD (Duke Cancer Institute).
Read more: hoosiercancer.org/collaborativ...

HCRN’s Report Reveals Key Trends Shaping Investigator-Initiated Oncology Trials - Hoosier Cancer Research Network Hoosier Cancer Research Network has released a new report, “Investigator-Initiated Oncology Trials: Trends, Challenges, and Opportunities,” that captures the experience and perspectives of more than 1...

We surveyed more than 130 researchers across our network, and 72% of them said IITs have been pivotal to their careers.
HCRN’s latest report explores how investigator-initiated trials are driving #oncology research forward.
Read more and download the report: hoosiercancer.org/hcrns-report...

HCRN’s new report shares insights from a survey of more than 130 researchers across our national network, revealing key trends, challenges, and the impact of IITs on cancer research.
Read more and download the report: hoosiercancer.org/hcrns-report...

Add-On Ramucirumab for EGFR-Mutant NSCLC RAMOSE and RELAY trial results

@medpagetoday.bsky.social published a writeup on HCRN-LUN18-335 (The "RAMOSE" study), which was led by Dr. Xiuning Le of the @mdanderson.bsky.social. This writeup was based on research published in @ascocancer.bsky.social's Journal of Clinical Oncology. Read more www.medpagetoday.com/reading-room...

Congratulations to HCRN co-founder Dr. Rafat Ansari, who will receive an honorary Doctor of Science degree from @notredame.bsky.social at its 180th University Commencement Ceremony on May 18!

Read more: news.nd.edu/news/notre-d...

We are excited to participate in the @ascocancer.bsky.social 2025 Annual Meeting in Chicago! Find us at booth #36117! Learn about our planned activities and featured abstracts at hoosiercancer.org/hcrns-presen... #ASCO2025

HCRN is looking for a passionate, dynamic communications and marketing coordinator who will help amplify our mission, reach new audiences, and elevate the impact of our research.

Learn more here: hoosiercancer.org/careers/#ope...

Come out to the Indiana Statehouse for Breast Cancer Advocacy Day on Monday! Hoosier Cancer Research Network will be on hand to share how we support researchers working to improve the lives of cancer patients through clinical trials. fox59.com/morning-news...

Study Highlight🧑‍⚕️🔬HCRN-GI23-643 is a randomized trial of regorafenib in combination with pembrolizumab or pembrolizumab monotherapy for patients with MSI-H colorectal cancer. Currently open to accrual at @adventhealth.bsky.social Orlando & @upmchillmancc.bsky.social. hoosiercancer.org/all-clinical...

HCRN launched an updated website with new features and a modernized design, developed in collaboration with THE PLAID AGENCY. Visit our new website and read more about it here: hoosiercancer.org/hcrn-launche...

FULL SHOW: Indiana Farmers Brace for Tariffs, Big Ten's Fight Against Cancer, and Rural Education YouTube video by Inside Indiana Business

Hoosier Cancer Research Network CEO Brian Stemme talked last week with Inside Indiana Business about the impact of the @bigtencrc.bsky.social and how the HCRN team supports this vital work. www.youtube.com/watch?v=MuCc...

Researchers participating in the HCRN-GU16-260 study have published a correlative analysis in Cancer Discovery. Congratulations to all co-authors and study teams whose hard work led to this publication! Read more: hoosiercancer.org/correlative-...

A HCRN non-small cell lung cancer study (RAMOSE trial) was published and featured in the February 1, 2025 issue of the Journal of Clinical Oncology. Congratulations to all co-authors and study teams whose hard work led to this publication!
Read more: hoosiercancer.org/hcrn-non-sma...

Congratulations to Dr. Deepak Kilari of @froedtert.bsky.social and all co-authors on presenting the ABATE study, HCRN-GU18-343! #GU25

Exciting findings from the HCRN GU18-343 ABATE study: A phase 2 trial evaluating cabozantinib + atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer! 🚀🔬 Don’t miss the insights at @ascocancer.bsky.social #GU25

Thank you to everyone who attended our GU Working Group meeting. We appreciate your time and contributions to the discussion! #GU25

Five HCRN studies presented at ASCO GU 2025, with HCRN-GU16-243 as a rapid oral abstract - Hoosier Cancer Research Network Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as […]

HCRN is set to participate in @ascocancer.bsky.social GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations. Read more: hoosiercancer.org/five-hcrn-st...

HCRN-LUN21-497 presented at SITC 2024 - Hoosier Cancer Research Network A Hoosier Cancer Research Network study, HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell […]

HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer,” was presented at SITC 2024 by Jeffrey Clarke, MD, of Duke University.

Read more: hoosiercancer.org/hcrn-lun21-4...

We are happy to announce our arrival on Bluesky! In addition to X, Facebook, and LinkedIn, you can now connect with us on here at @hoosiercancer.bsky.social. Follow us and join the growing conversation!

Thank you to all investigators who joined the HCRN GI Clinical Trial Working Group meeting this morning. Great discussion on new concepts and current studies. #GI25 #OncSky #MedSky

HCRN-GI23-643 will be presented as a Trials in Progress poster at the @ascocancer.bsky.social Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.

Read more: hoosiercancer.org/hcrn-gi23-64...

HCRN-GU16-243 presented at SUO 2024 - Hoosier Cancer Research Network A correlative study related to the Hoosier Cancer Research Network (HCRN) clinical trial, HCRN-GU16-243, titled, “A Phase 1 Trial of Durvalumab in Combination with Bacillus […]

A correlative study related to HCRN-GU16-243 was presented at #SUO2024 by Noah Hahn, MD, of Sidney Kimmel Comprehensive Cancer Center.

Congratulations to Dr. Hahn and co-authors!

Read more: hoosiercancer.org/hcrn-gu16-24...

Congrats to Rana Mckay of UC San Diego Health Moores Cancer Center on being elected to the @ascocancer.bsky.social Nominating Committee! She serves as a co-chair of the our GU Clinical Trial Working Group & is a sponsor-investigator of multiple HCRN studies.

connection.asco.org/do/dr-elizab...

The NePtune study tests if combining olaparib + hormone therapy before surgery can reduce cancer & recurrence in prostate cancer patients with DNA repair mutations. It aims to improve outcomes for men with aggressive localized prostate cancer.
Learn more: www.facingourrisk.org/blog/what-is...

We are grateful to all who joined the HCRN #breastcancer research meeting at #SABCS24. Great discussion on currently enrolling studies and potential new multi-center IITs.

Thank you to our #myeloid working group members for a fantastic lunch discussion during #ASH24.

Fantastic lunch meeting with Hoosier Cancer Research Network #lymphoma researchers during #ASH24. Thank you to all who attended and contributed to such a productive discussion.

An HCRN clinical trial is open for subjects with brain metastases from triple negative or BRCA-mutated breast cancers. Learn more: hoosiercancer.org/clinical-tri...